MARKET

OBIO

OBIO

Orchestra BioMed Holdings Inc
NASDAQ
4.340
+0.040
+0.93%
Closed 16:27 12/18 EST
OPEN
4.390
PREV CLOSE
4.300
HIGH
4.560
LOW
4.280
VOLUME
82.92K
TURNOVER
0
52 WEEK HIGH
6.30
52 WEEK LOW
2.200
MARKET CAP
245.06M
P/E (TTM)
-2.3868
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OBIO last week (1208-1212)?
Weekly Report · 4d ago
Orchestra BioMed Holdings Price Target Announced at $15.00/Share by TD Cowen
Dow Jones · 12/10 16:12
TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15
Benzinga · 12/10 16:03
ORCHESTRA BIOMED HOLDINGS INC <OBIO.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $15
Reuters · 12/10 11:56
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Insmed (INSM) and Orchestra BioMed Holdings (OBIO)
TipRanks · 12/10 10:50
Orchestra BioMed Showcases AVIM Therapy and Virtue SAB at ICI Meeting
Reuters · 12/08 12:00
ORCHESTRA BIOMED ANNOUNCES AVIM THERAPY AND VIRTUE SAB PROGRAM PRESENTATIONS AT ICI MEETING
Reuters · 12/08 12:00
Weekly Report: what happened at OBIO last week (1201-1205)?
Weekly Report · 12/08 09:24
More
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Webull offers Orchestra Biomed Holdings Inc stock information, including NASDAQ: OBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OBIO stock methods without spending real money on the virtual paper trading platform.